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Abstract  
Short chain fatty acids (SCFAs), produced as by-products of dietary fibre metabolism by gut bacteria, 
have anti-inflammatory properties and could potentially be used for the treatment of inflammatory 
diseases, including asthma. The direct effects of SCFAs on inflammatory responses in primary human 
lung mesenchymal cells have not been assessed. We investigated whether SCFAs can protect against 
TNFα-induced inflammation in primary human lung fibroblasts (HLFs) and airway smooth muscle 
(ASM) cells in vitro.  
HLFs and ASM cells were exposed to SCFAs, acetate (C2:0), propionate (C3:0) and butyrate (C4:0) 
(0.01mM-25mM) with or without TNFα, and the release of pro-inflammatory cytokines, IL-6 and 
CXCL8, was measured using ELISA. We found that none of the SCFAs suppressed TNFα-induced 
cytokine release. On the contrary, challenge with supra-physiological concentrations (10mM-25mM) 
as might be used therapeutically of propionate or butyrate in combination with TNFα resulted in 
substantially greater IL-6 and CXCL8 release from HLFs and ASM cells than challenge with TNFα 
alone, demonstrating synergistic effects. In ASM cells challenge with acetate also enhanced TNFα-
induced IL-6, but not CXCL8 release. 
Synergistic upregulation of IL-6 and CXCL8 was mediated through the activation of free fatty acid 
receptor (FFAR)3, but not FFAR2. The signalling pathways involved were further examined using 
specific inhibitors and immunoblotting, and responses were found to be mediated through p38 MAP 
kinase signalling. This study demonstrates that pro-inflammatory, rather than anti-inflammatory 
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Introduction  
Asthma affects nearly 300 million people worldwide and is characterised by chronic airway 
inflammation. Anti-inflammatory treatments such as corticosteroids are commonly used to treat the 
disease, however around 10% of patients with severe asthma are refractory to these medications. In 
addition severe side effects are often observed when steroids are used at high doses, therefore new 
well-tolerated anti-inflammatory therapeutics are needed (43).  
There is increasing evidence implicating the gut microbiota as a critical contributor to host health 
and immune homeostasis in inflammatory diseases including type-2 diabetes, obesity, chronic 
obstructive pulmonary disease and asthma (4, 5, 48). The prevailing hypothesis is that gut bacteria 
produce short-chain fatty acids (SCFAs) that are directly anti-inflammatory, as by-products of dietary 
fibre metabolism. SCFAs are fatty acids with fewer than 6 carbon (C) atoms. Important sources of 
dietary fibre are fruit and vegetables and the most abundant metabolites produced are acetate 
(C2:0), propionate (C3:0) and butyrate (C4:0). In the large intestine, SCFAs occur at concentrations 
ranging from 30 to 150mM. They are absorbed into the portal circulation and reach the bloodstream 
(0.1-5mM), where they potentially elicit anti-inflammatory effects. SCFAs can also be detected in 
sputum (0.1-5mM), indicating that they reach the lungs and airways (11). Possible mechanisms by 
which SCFAs elicit their effects are through the inhibition of histone deacetylases (HDACs) and 
activation of G-protein coupled receptors (GPCRs) such as GPR43 and GPR41, also known as free 
fatty acid receptor (FFAR)2 and FFAR3 leading to consequent effects on gene transcription. FFARs 
are surface receptors found on cells of the gastrointestinal tract, as well as immune cells (e.g., 
neutrophils and monocytes) and adipocytes (52). We recently showed that lung mesenchymal cells 
also express these receptors (37). FFARs differ in their affinity for SCFAs. FFAR2 has a similar affinity 
for acetate, propionate and butyrate, while FFAR3 has greater affinity for propionate than butyrate 
and low affinity for acetate (45). 
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The potential beneficial effects of SCFAs in asthma have not been extensively studied. However, 
recent mouse-model studies showed that dietary fibre and propionate protect against allergic 
airway disease and maternal intake of dietary fibre has been associated with a reduced asthma 
phenotype in the offspring (42, 44). In addition, a recent human pilot study showed acute reductions 
in airway inflammation biomarkers, including sputum CXCL8, eNO and sputum inflammatory cell 
counts after consuming a high soluble fibre meal (13). However, more studies are needed to 
determine the potential beneficial effects of SCFAs in asthma. In vitro studies using colonic epithelial 
cells and different immune cells, including neutrophils and macrophages, show that SCFAs are anti-
inflammatory, as shown by reduced chemotaxis and pro-inflammatory cytokine and reactive oxygen 
species release in response to inflammatory stimuli (6, 47, 52). However, the direct effects of SCFAs 
in human lung mesenchymal cells have not been investigated.  
Tumour necrosis factor (TNF)-α is a multi-potent pro-inflammatory mediator, mainly produced by 
macrophages, and has been implicated in the pathology of asthma. Serum TNFα levels are increased 
in the airways of asthma patients and are positively correlated with the severity of the disease (19, 
38). TNFα plays a critical role in the immunoregulation of asthma by contributing to 
bronchopulmonary inflammation and airway hyperresponsiveness. TNFα might also contribute to 
refractory asthma through the recruitment of neutrophils and the induction of glucocorticoid 
resistance (3). 
We hypothesised that SCFAs could potentially be used for the treatment of asthma, specifically to 
reduce inflammatory responses in the lungs and airways via the activation of FFAR2 and/or 3. The 
aim of this study was to investigate the direct effects of SCFAs on inflammatory responses in primary 
human lung mesenchymal cells, in vitro. Since TNFα-induced cytokine release is steroid insensitive, 
we used this to challenge human lung fibroblasts (HLFs) and airway smooth muscle (ASM) cells and 
examined whether SCFAs could protect against TNFα-induced inflammation, by measuring the 
release of pro-inflammatory mediators. 
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Methods  
Cell culture  
HLFs were isolated from the parenchyma and ASM cells from the bronchial airways of lungs from 
patients undergoing lung transplantation or lung resection for thoracic malignancies, as previously 
described (15, 23). Ethical approval for all experiments was provided by The University of Sydney 
Human Ethics Committee and the Sydney South West Area Health Service, and written informed 
consent was obtained. Table 1 shows the patient demographics. HLFs and ASM cells were seeded in 
12-well or 6-well plates at a density of 6.2 x 104 cells/mL in DMEM medium containing 5% fatal 
bovine serum (FBS) and 1% Antibiotic-Antimycotic (Gibco, Grand Island, New York, US) and grown to 
sub confluence (3 days). HLFs and ASM cells were quiesced for 24 hours prior to stimulation by 
incubation in DMEM (Gibco, Grand Island, New York, US) supplemented with 0.1% bovine serum 
albumin (BSA) (Sigma Aldrich, Castle Hill, NSW, Australia) and 1% Antibiotic-Antimycotic. 
We also used the human monocyte cell line THP-1 (ATCC, Manassas, VA). THP-1 cells were 
maintained in RPMI 1640 medium (Gibco), supplemented with 10% FBS, 1% antibiotic-antimycotic 
and 1% HEPES (Gibco). THP-1 cells were seeded at a density of 1 x 106 cells/mL in 12-well plates and 
treatments were added. All experiments were carried out using HLFs and ASM cells between 
passage 2 and 5, and THP-1 cells between passage 3 and 6. 
Treatment of cells with SCFAs and FFAR agonists 
Cells were unstimulated (control) or stimulated with propionate (0.5mM-25mM), butyrate (0.01mM-
10mM), acetate (0.5mM-25mM) (Sigma Aldrich, Castle Hill, NSW, Australia), FFAR2 agonist 4-CMTB 
(10µM) (Sigma), FFAR3agonist AR420626 (10µM) (Sigma), FFAR3 antagonist β-hydroxybutyrate 
(BOH) (100mM) (Sigma) or vehicle (0.1% DMSO) for 24h or 96h, with or without TNFα (1ng/mL) 
(ThermoFisher, Scoresby, VIC, Australia) or LPS (1µg/mL) (Sigma) for another 12 or 24h. The total 
incubation time was 36, 48 or 120h. All cells were incubated at 37°C with 5% CO2.  
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Inhibition of signaling pathways 
HLFs were treated with inhibitors of p38 mitogen-activated protein kinase (MAPK) (SB239063, 3µM) 
(Tocris, Ellisville, MO, USA), MAP kinase 1 (MEK1) (PD98059, 10µM), c-Jun N-terminal kinase (JNK) 
(SP600125, 10µM), (Calbiochem, San Diego, CA, USA), COX (indomethacin, 10µM) and NF-κB (BAY-
117082, 1µM) (Sigma-Aldrich) for 1 hour before stimulation with propionate (25mM) with or 
without TNFα (1ng/mL). 
ELISA  
Levels of IL-6 and CXCL8 in supernatants were measured using commercial antibody kits according to 
the manufacturer’s instructions (R&D Systems, Minnesota, USA). The detection limit of both assays 
was 15.6pg/ml. 
Quantitative PCR 
Total RNA was extracted using the ISOLATE II RNA Mini Kit and transcribed into cDNA using the 
SensiFAST™ cDNA Synthesis Kit (Bioline, Alexandria, Australia). qPCR was performed using the 
StepOne Plus detection system and data were analysed with StepOne software (Applied Biosystems, 
Melbourne, Australia). Assays were carried out in triplicate using a reaction mixture containing the 
Bioline SensiFAST Probe Hi-ROX Master Mix, primer for IL-6 or CXCL8 and for ubiquitously expressed 
ribosomal RNA (18S rRNA) as a housekeeping gene. Relative expression was normalised to 18S rRNA 
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Western blotting 
To assess the activation of intracellular signaling molecules in HLFs following stimulation with 
propionate with or without TNFα, relative levels of phosphorylated p38 MAPK, JNK, ERK, Akt and  
NF-κB from cell lysates were assessed by western blotting. Cells cultured in the presence or absence 
of propionate (25mM) with or without TNFα (1ng/mL) for 30 min were lysed (20mM Tris, pH 7.4, 
150mM NaCl, 1mM Na2EDTA, 1mM EGTA, 20mM NA4P2P7, 2mM Na3VO4, 1% Triton X- 100, 10% 
glycerol, 0.1% SDS, 0.5% sodium deoxycholate, 1% protease inhibitor cocktail set III (Millipore, USA) 
and 1mM phenylmethylsulfonyl fluoride (PMSF) (Amresco, Solon, OH, USA). Cell lysates were 
separated by SDS/polyacrylamide gel electrophoresis (SDS-PAGE) on 10% gels and transferred to 
polyvinylidene difluoride (PVDF) membranes using a Trans-Blot Turbo transfer system (Bio-Rad). The 
membranes were incubated with rabbit anti-phospho p38 MAPK (Thr180/Tyr182) (No. 9211) , rabbit 
anti-p38 MAPK (No. 9212), rabbit anti-phospho SAPK/JNK (Thr183/Tyr185) (No. 9251), rabbit anti-
SAPK/JNK (No. 9252), rabbit anti-phospho ERK (Thr202/Tyr204) (No. 9101), rabbit anti-ERK (No. 
9102), rabbit anti-phospho AKT (Thr308) (244F9) (No. 4056), rabbit anti-AKT (No. 9272), rabbit anti-
phospho NF-κB p65 (Ser536) (93H1) (No. 3033), rabbit anti-NF-κB p65 (D14E12) XP (No. 8242) (all 
1:1000, Cell Signaling Technology) or anti-mouse glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (MAP374) (1:5000, Merck Millipore, USA) overnight at 4°C. After washing with Tris-
buffered saline-containing Tween 20 (0.05%), bound antibody was visualized using horseradish 
peroxidase-conjugated goat anti-rabbit IgG or horseradish peroxidase-conjugated anti-mouse IgG 
antibody (Dako, USA) and enhanced chemiluminescence, and imaged (Image Station 4000MM; 
Kodak Digital Science, New Haven, CT). GAPDH served as the control. 
Statistical analysis 
Statistical analysis was conducted using GraphPad Prism version 7 software (San Diego, CA, USA). 
Comparisons of data were carried out using one-way ANOVA with repeated measures followed by a 
Bonferroni post-test, where appropriate unless otherwise specified. A probability (p) value of less 
than 0.05 was considered significant.  
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Results  
Stimulation with propionate or butyrate and TNFα increases cytokine release from fibroblasts.  
To assess whether SCFAs inhibit the inflammatory response to TNFα in human lung mesenchymal 
cells, HLFs (n = 10-24) were challenged with propionate, butyrate or acetate prior to stimulation with 
TNFα, and IL-6 and CXCL8 release was measured. None of the SCFAs supressed TNFα-induced 
cytokine release. Challenge with propionate (25mM), butyrate (10mM) and acetate (25mM) alone 
did not induce cytokine release from HLFs (Figure 1A-F). However, challenge with the combination of 
propionate (10mM and 25mM) and TNFα (1ng/ml) resulted in substantially greater IL-6 (p<0.05) and 
CXCL8 (p<0.001) release than challenge with TNFα alone (Figure 1A and 1B). The effect of the 
combination of propionate and TNFα on IL-6 and CXCL8 release was greater than the sum of the 
individual effects of propionate and TNFα, demonstrating a synergistic effect. Challenge with 
butyrate (10mM) and TNFα also resulted in greater IL-6 (p<0.001) and CXCL8 (p<0.0001) release, 
than TNFα alone (Figure 1C and 1D). There was no interaction between acetate and TNFα (Figure 1E 
and 1F). 
Stimulation with propionate and TNFα increases IL-6 and CXCL8 mRNA expression in fibroblasts. 
Next, we assessed whether propionate increases TNFα-induced IL-6 and CXCL8 mRNA expression 
using qPCR. Challenge with the combination of propionate (25mM) and TNFα (1ng/ml) resulted in 
substantially greater mRNA expression of IL-6 (n = 8, p<0.05) and CXCL8 (n = 8, p<0.05) (Figure 2) 
than challenge with TNFα alone at both time points (12h and 24h). The effect of the combination of 
propionate and TNFα on IL-6 and CXCL8 mRNA expression was greater than the sum of the individual 
effects of propionate and TNFα, again demonstrating synergistic effects. 
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SCFAs enhance TNFα-induced IL-6 and CXCL8 release through FFAR3 signalling.  
To investigate whether these pro-inflammatory effects are mediated through activation of FFAR2 
and/or FFAR3, HLFs were challenged with specific agonists for FFAR2 (4-CMTB) or FFAR3 
(AR420626), prior to stimulation with TNFα. Challenge with the combination of AR420626 (10µM), 
but not 4-CMTB, and TNFα resulted in greater IL-6 (n = 14, p<0.05) and CXCL8 (n = 14, p<0.001) 
release than TNFα alone (Figure 3A-3D), suggesting the activation of FFAR3, but not FFAR2 to be the 
signalling mechanism for SCFAs. To further confirm the involvement of FFAR3 signalling, HLFs were 
incubated with FFAR3 antagonist BOH (100mM) for 60 minutes prior to challenge with the 
combination of propionate (10mM) and TNFα.  Blocking of FFAR3 signalling with BOH suppressed 
propionate and TNFα-induced IL-6 (n = 8, p<0.05) and CXCL8 release (n = 8, p<0.01) (Figure 3E and 
3F)  Stimulation with propionate and TNFα leads to hyperactivation p38 MAPK. To investigate the 
mechanisms underlying the effects of combined propionate and TNFα-induced IL-6 and CXCL8 
release, we used protein immunoblotting to investigate the activation of signalling pathways. We 
focussed on five known major signalling pathways (NF-κB, p38 MAPK, AKT, ERK and SAPK/JNK), all of 
which have been shown to stimulate IL-6 and/or CXCL8 production (22, 26, 36, 41). Phosphorylation 
of NF-κB was increased 30 minutes after stimulation with TNFα alone (n = 10, p<0.01), but was not 
increased by concomitant treatment with propionate (p<0.01) (Figure 4A). p38 MAPK 
phosphorylation was increased upon challenge with propionate alone (n = 10, p<0.05), TNFα alone 
(p<0.01) and the combination of propionate and TNFα (n = 10, p<0.01) (Figure 4C). The combination 
of propionate and TNFα led to greater phosphorylation of p38 MAPK, than TNFα alone (p<0.05), 
showing hyperactivation of this pathway. Phosphorylation of AKT did not increase with any of the 
treatments (Figure 4E) and phosphorylation of ERK was increased upon challenge with TNFα alone (n 
= 10, p<0.01), but not in combination with propionate (Figure 4G). Finally, phosphorylation of JNK 
was increased upon challenge with TNFα alone (n = 10, p<0.05) and the combination of propionate 
and TNFα (p<0.01) (Figure 4I). Total NF-κB, p38 MAPK, AKT, ERK and SAPK/JNK did not change with 
any treatment (Figure 4B, D, F, H, J).  
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Inhibition of p38 MAPK suppresses and propionate and TNFα-induced cytokine release. To further 
investigate and confirm the mechanisms underlying the effects of propionate and TNFα-induced IL-6 
and CXCL8 release, specific inhibitors were used to block COX, p38 MAPK, JNK, NF-κB or MEK 
activation, at concentrations previously shown to be effective in human airway cells (7, 10, 12, 14, 
17, 49). Inhibition of COX, JNK or MEK did not suppress cytokine release induced by propionate in 
combination with TNFα or TNFα alone. However, inhibition of p38 MAPK with SB239063 suppressed 
IL-6 (n = 10, p<0.05) and CXCL8 (n = 10, p<0.05) release induced by TNFα alone (Figure 5A and 5B) 
and by the combination of propionate and TNFα (n = 11, p<0.05 for IL-6 and p<0.01 for CXCL8) 
(Figure 5C and 5D). Inhibition of NF-κB suppressed IL-6 (p<0.05), but not CXCL8 release, induced by 
propionate in combination with TNFα. This suggests p38 MAPK to be the main pathway. However, 
the only partial (30-60%) inhibition of propionate and TNFα-induced cytokine release achieved by 
blocking the p38 MAPK signaling pathway, indicates that other pathways are also involved.Chronic 
exposure of SCFAs also enhances TNFα-induced cytokine release from fibroblasts 
To explore whether chronic exposure to SCFAs has similar effects as acute exposure, HLFs (n = 7) 
were challenged with propionate (25mM), butyrate (10mM) or acetate (25mM) for 96h before TNFα  
was added for another 24h. Challenge with propionate or butyrate, but not acetate led to 
substantially greater IL-6 (p<0.01) and CXCL8 (p<0.001), than challenge with TNFα alone (Figure 6). 
These results demonstrate that chronic or acute exposures of SCFAs have similar effects on TNFα-




Stimulation with acetate, propionate or butyrate and TNFα increases cytokine release from ASM 
cells. To explore whether other lung mesenchymal cells respond in a similar way to HLFs, we 
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repeated selected experiments in primary human ASM cells (n = 8-20). The combination of 
propionate (10mM and 25mM) and TNFα resulted in substantially greater IL-6 (p<0.01) and CXCL8 
release (p<0.01), than challenge with TNFα alone (Figure 7A and 7B). Challenge with butyrate 
(10mM) and TNFα also resulted in greater IL-6 (10mM) (p<0.05) and CXCL8 release (p<0.01), than 
TNFα challenge alone (Figure 6C and 6D). The combination of acetate (10mM and 25mM) and TNFα 
had no effect on IL-6, but resulted in greater CXCL8 (p<0.01) release from ASM cells (Figure 7E and 
7F). Thus, challenge of ASM cells shows similar effects as in the HLFs. 
Propionate suppresses LPS-induced CXCL8 release from THP-1 monocytes. Our findings show that 
SCFAs have pro-inflammatory and not anti-inflammatory effects on lung mesenchymal cells. This 
contradicts our hypothesis, as well as published literature demonstrating that SCFAs are generally 
anti-inflammatory including in white blood cells such as monocytes (33). To confirm and replicate 
these findings in our study, THP-1 cells were challenged with acetate, propionate or butyrate prior to 
stimulation with LPS, and CXCL8 release was measured. Propionate (25mM), but not acetate or 
butyrate suppressed LPS-induced CXCL8 release from THP-1 cells (n = 7, p<0.001) (Figure 8A-C). 
None of the SCFAs increased LPS-induced cytokine release, demonstrating that the pro-






This study is the first to investigate whether SCFAs directly suppress innate immune responses in 
primary human lung mesenchymal cells. We found that the SCFAs propionate, butyrate or acetate 
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did not suppress TNFα-induced cytokine release from HLFs. Furthermore, challenge with high 
concentrations (10mM and 25mM) of propionate in combination with TNFα led to greater IL-6 and 
CXCL8 release than TNFα alone. The effect of the combination of propionate and TNFα on cytokine 
release was substantially greater than the sum of the individual effects of propionate or TNFα alone 
which indicates that the effects are synergistic. Butyrate, but not acetate also increased TNFα-
induced cytokine release, although the effect on IL-6 release was less profound compared to 
propionate. These effects were observed with acute (24h) and chronic exposure (96h) of SCFAs.  
Several studies have demonstrated that SCFAs have therapeutic potential in protecting against 
allergic airways disease in animal models (42, 44), and asthma in human studies (13), potentially 
through their anti-inflammatory properties. SCFAs have been shown to inhibit the production of pro-
inflammatory mediators such as TNFα in LPS-stimulated immune cells, including neutrophils, 
monocytes and macrophages (30, 34, 51). Inhibitory effects have also been observed in human 
intestinal cell lines, with reduced LPS-induced CXCL8 release, associated with the inhibition of HDAC 
activity (1). However, not all studies have reported anti-inflammatory effects. SCFAs have also been 
shown to increase pro-inflammatory cytokine production in toll like receptor (TLR)-stimulated 
polymorphonuclear cells and epithelial cells in vitro (28, 32) and well as in a mouse-model study (20). 
In addition, orally administered SCFAs have been shown to induce inflammation in the renal system 
in mice (35). Moreover, there is evidence for SCFA enhancement of neutrophil chemotaxis in mouse-
model studies (50). In bronchial epithelial cells, depending on the concentration of SCFAs, either 
inhibitory or stimulatory effects on pro-inflammatory cytokine production are observed (11). Thus, 
observations of the effects of SCFAs on inflammatory processes in immune cells and structural cells 
are divergent. They can be pro- or anti-inflammatory depending on the cell type that is studied and 
on the conditions, type and concentration of SCFA and type of co-stimulation. The concentrations of 
SCFAs used in this study were chosen based on concentrations found in the colonic lumen (30-
150mM), the airways (0.1-5mM) and from previous studies, and based on individual concentrations 
of SCFAs with acetate being the most prevalent followed by propionate and butyrate, respectively 
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(11, 55). To investigate the use of SCFAs as a therapeutic strategy, we also used concentrations that 
are higher than physiological concentrations, as typically occurs when exogenous cytokines, 
prostaglandins or other mediators are used as a therapeutics. We examined the release of IL-6 and 
CXCL8 from mesenchymal cells, as these are pro-inflammatory mediators and are important in the 
pathogenesis of asthma (2). IL-6 is a marker of systemic inflammation and its levels are increased in 
the serum and BAL fluid of asthma patients. Increased IL-6 levels have also been associated with 
asthma exacerbations, disease severity and poor lung function (25). CXCL8 is a potent neutrophil 
chemoattractant, and its levels are increased in sputum in severe asthma patients and during virus-
induced asthma exacerbations (2).  
This is the first study to investigate the direct effects of SCFAs specifically in primary HLFs. HLFs are 
one of the main structural cells in the airway wall and play an important role in inflammation and 
the production of potent pro-inflammatory mediators, including IL-6 and CXCL8, and provide a good 
representation of airway mesenchymal cells (16, 18). In addition, fibroblasts are located at the 
interface of the airway lumen and the blood supply and are directly exposed to constituents of tissue 
fluids (plasma), including SCFAs which are present in millimolar concentrations. Hence, these cells 
are likely to be key cells in driving inflammatory responses to serum derived factors in asthma and 
consequently our study primarily focussed on pulmonary fibroblasts. 
A possible mechanism by which SCFAs elicit biological responses is the activation of FFAR2 and/or 
FFAR3. These two GPCRs share around 40% peptide sequence, but differ in their tissue distribution, 
physiological roles and affinity for SCFAs. FFAR2 has a similar affinity for acetate, propionate and 
butyrate, whereas FFAR3 has a greater affinity for propionate than butyrate and the lowest affinity 
for acetate. Acetate mainly activates FFAR2, propionate mainly activates FFAR3, and butyrate 
equally activates FFAR2 and FFAR3 (24, 45). Despite growing interest in these receptors, many 
questions regarding their function and effect on inflammatory responses remain unanswered. 
Studies using FFAR2 (GPR43) and/or FFAR3 (GPR41) deficient (-/-) mice show inconsistent results; 
Maslowski and colleagues showed that FFAR2 was necessary for the resolution of a number of 
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inflammatory responses in models of colitis and asthma using FFAR2-/- and germ-free mice, 
however, not all studies confirm these findings (29). Sina et al. showed that FFAR2-/- mice had 
reduced polymorphonuclear leucocyte infiltration that was associated with less tissue damage in a 
mouse-model of colitis (39). These results suggest a potential pro-inflammatory role of FFAR2 in 
colitis. Trompette and colleagues, however, showed that a high fibre diet led to a reduction in 
inflammatory markers, including eosinophil infiltration and goblet cell hyperplasia in a mouse-model 
of allergic asthma compared to a low fibre diet (44). This finding was also observed in FFAR2-/- but 
not FFAR3-/- animals, suggesting that activation of FFAR3 is protective. In addition, in vitro studies 
using bronchial epithelial cells from cystic fibrosis patients found increased release of the pro-
inflammatory mediator CXCL8 upon stimulation with SCFAs that was reduced by siRNA knockdown 
of FFAR3 (31). In this study, we investigated whether activation of FFAR2 and/or FFAR3 is 
responsible for the observed pro-inflammatory effect of propionate using specific synthetic agonists 
for these receptors. We used 4-CMTB, which is a selective allosteric ligand for FFAR2 (40), and 
AR420626, which is a selective agonist of FFAR3 that does not activate FFAR2 at concentrations up 
to 100μM (9). Interestingly, we found that AR420626, but not 4-CMTB in combination with TNFα, 
resulted in greater IL-6 and CXCL8 release, than challenge with TNFα alone. These results suggest 
that activation of FFAR3, but not FFAR2 enhances the pro-inflammatory effects of TNFα in HLFs. This 
could also explain the lack of pro-inflammatory effect of acetate in HLFs, as acetate primarily acts on 
FFAR2. We further confirmed these findings using the FFAR3 antagonist BOH. Several studies have 
shown BOH to inhibit FFAR3 signalling in vitro (21, 27, 54). We found that BOH pre-treatment 
suppressed propionate and TNFα-induced IL-6 and CXCL8 release, providing further evidence for 
FFAR3 to be the main signalling pathway. 
We also demonstrated that propionate increases TNFα-induced IL-6 and CXCL8 mRNA expression, 
indicating that the transcription of these cytokines is enhanced. To further understand the 
mechanisms involved, signaling pathways were investigated using protein immunoblotting. We 
focussed on five main signalling pathways, NF-κB, p38 MAPK, AKT, ERK and SAPK/JNK, all of which 
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have been shown to stimulate IL-6 and/or CXCL8 production (22, 26, 36, 41). We demonstrated that 
in HLFs, TNFα alone activates NF-κB, p38 MAPK, ERK and JNK, but not AKT signalling. TNFα is known 
to stimulate multiple signal transduction pathways, including JNK, p38 and NF-κB, resulting in IL-6 
and CXCL8 release in other cell types (8, 53). More importantly, we found that hyperactivation of 
p38 MAPK is the underlying mechanism for the pro-inflammatory effects of propionate as challenge 
with this SCFA alone led to an increase in phosphorylation of p38 MAPK, and the combination of 
propionate and TNFα resulted in greater p38 MAPK phosphorylation than TNFα alone. We further 
investigated and confirmed the mechanisms involved in propionate and TNFα-induced IL-6 and 
CXCL8 release using specific signaling inhibitors. SB239063 is a potent and selective inhibitor of p38 
MAPK and displays specific and high-affinity binding (IC50 = 44nM) (46). It suppressed IL-6 and CXLC8 
release induced by TNFα alone and by the combination of propionate and TNFα. Inhibition of NF-κB 
partially suppressed IL-6, but not CXCL8 release induced by propionate and TNFα. These results 
confirm that p38 MAPK signalling is the main signal transduction pathway responsible for propionate 
and TNFα-induced cytokine release.   
To explore whether other structural lung cells respond in the same way as pulmonary fibroblasts, we 
repeated selected experiments in primary ASM cells. In ASM cells, propionate and butyrate in 
combination with TNFα also resulted in synergistic cytokine release, but the effect of butyrate was 
less profound compared to propionate. These results show that SCFAs have similar effects in ASM 
cells and HLFs. Interestingly, acetate also enhanced TNFα-induced CXCL8, but not IL-6 release from 
ASM cells, indicating that this SCFA has pro-inflammatory effects in ASM cells, but not HLFs. These 
results show different cells respond differently in some way to SCFAs, but the consistent observation 
is that propionate and butyrate are the most potent SCFAs in enhancing pro-inflammatory effects in 
primary lung mesenchymal cells. This is interesting, as based on previous findings from others, we 
expected SCFAs to be anti-inflammatory and potentially beneficial in reducing inflammation in 
asthma, but found opposite results in lung mesenchymal cells.  
We next used a monocyte cell line (THP-1) and investigated whether SCFAs suppressed LPS-induced 
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CXCL8 release, and found an inhibitory effect of propionate. These results confirm SCFAs to have 
both anti-inflammatory and pro-inflammatory effects, depending on the stimulus and cell type 
studied. Although the studies in this manuscript utilized primary human mesenchymal cells, an 
important limitation of this study is that all studies were done in vitro. In future studies effects of 
SCFAs on inflammatory markers will be investigated using an in vivo model. In summary, this study 
demonstrates that exposure of primary HLFs and ASM cells to supra-physiological concentrations of 
SCFAs synergistically enhances TNFα-induced inflammatory responses, as measured by IL-6 and 
CXCL8 release, through activation of FFAR3 and p38 MAPK signalling. Contrary to our hypothesis, 
this study demonstrates that pro-inflammatory, rather than anti-inflammatory effects of SCFAs are 
evident in lung mesenchymal cells. 
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Table 1. Summary of patient demographics 
 
Table 1. Patient demographics (n = 58)   










(pack years)  
Medication before surgery  LTOT  
(yes/no) 
 Experiments  
1.  HLF sarcoidosis/ 
pulmonary fibrosis 
50 M T N/A budesonide/formoterol, terbutaline N/A qPCR, inhibitors, FFAR agonists 
2.  HLF NSCLC 62 M R Non-smoker travoprost No qPCR, inhibitors, FFAR agonists 
3.  HLF tumour  70 F R Ex-smoker  
(45 pack years) 
tiotropium, budesonide/formoterol, ezetimibe, rosuvastatin, felodipine, 
sertraline, indapamide. 
No qPCR, inhibitors, FFAR agonists 
4.  HLF  COPD 55 M T Ex-smoker  
(30 pack years) 
tiotropium, fluticasone/salmeterol, salbutamol, prednisolone No qPCR, inhibitors, FFAR agonists 
5.  HLF COPD 52 F T Ex-smoker  
(50 pack years) 
venlafaxine, prednisolone, fluticasone/salmeterol, tiotropium No qPCR,  SCFAs + TNFα, inhibitors,  
FFAR agonists, WB 
6.  HLF adenocarcinoma 64 F R Ex-smoker  levothyroxine, telmisartan, furosemide, spironolactone, rosuvastatin, 
warfarin 
No qPCR,  SCFAs + TNFα, inhibitors, 
FFAR agonists, WB 
7.  HLF sarcoidosis  46 M T Ex-smoker  
(<2 pack years) 
methotrexate, folinic acid, budesonide/formoterol, amoxicillin/clavulanic 
acid, omeprazole 
No qPCR,  SCFAs + TNFα, inhibitors,  
FFAR agonists, WB 
8.  HLF emphysema  54 M T Ex-smoker  
(60 pack years) 
N/A Yes qPCR,  SCFAs + TNFα, inhibitors, 
FFAR agonists, WB 
9.  HLF IPF 58 F T N/A salbutamol, warfarin, pravastatin, tralokinumab, fenofibrate, celecoxib, 
levothyroxine, mometasone  
No SCFAs + TNFα 
10.  HLF COPD 56 F T Ex-smoker  
(120 pack years)  
fluticasone/formoterol, tiotropium, pantoprazole, terbutaline Yes SCFAs + TNFα 
11.  HLF Emphysema 59 M T Current  
(35 pack years) 
fluticasone/formoterol, prednisolone, salbutamol, tiotropium, meloxicam, 
doxycycline, ipratropium, glycopyrronium bromide, tapentadol, oxycodone, 
rabeprazole, pregabalin 
No SCFAs + TNFα 
12.  HLF  pulmonary 
hypertension 
36 M T Non-smoker dobutamine, bumetanide, empagliflozin, entecavir, folic acid, gabapentin No SCFAs + TNFα 
13.  HLF emphysema  62 F T  Ex-smoker  
(40 pack years) 
terbutaline, ciclesonide, tiotropium, formoterol, salbutamol, ipratropium, 
irbesartan, rosuvastatin, prednisolone, azithromycin, pantoprazole 
Yes  SCFAs + TNFα, FFAR agonists, WB 
14.  HLF IPF 57 M T Ex-smoker  
(40 pack years) 
sildenafil, bumetanide, fluticasone/formoterol, salbutamol Yes SCFAs + TNFα, FFAR agonists, WB 
15.  HLF IPF 62 M T Ex-smoker  
(10 pack years) 
N/A N/A SCFAs + TNFα, FFAR agonists, WB 
16.  HLF NSCLC 72 F R Ex-smoker  
(>20 pack years) 
telmisartan, propionate/salmeterol, furosemide, ranitidine. No SCFAs + TNFα, FFAR agonists, WB 
17.  HLF adenocarcinoma 57 F R N/A  N/A  No SCFAs + TNFα, FFAR agonists, WB 
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18.  HLF IPF 63 M T Ex-smoker 
(>40 pack years) 
prednisone, pantoprazole, lorazepam, escitalopram, morphine Yes  SCFAs + TNFα,  
FFAR agonists, WB 
19.  HLF IPF 52 M T Ex-smoker  
(15 pack years) 
clonazepam, esomeprazole, clotrimazole, hydrocortisone, irbesartan, 
nintedanib, paracetamol, rosuvastatin, temazepam, trimethoprim/ 
sulfamethoxazole, 
Yes SCFAs + TNFα , inhibitors, WB 
20.  HLF sarcoidosis/ 
pulmonary 
hypertension  
57 M T Non-smoker prednisolone, sildenafil, warfarin, ambrisentan Yes SCFAs + TNFα , inhibitors, WB 
21.  HLF IPF 63 F T Ex-smoker  
(15 pack years) 
gabapentin, lorazepam, pantoprazole, prednisolone, sildenafil, 
trimethoprim/sulfamethoxazole 
Yes  SCFAs, inhibitors, WB 
22.  HLF IPF 55 M T Ex-smoker  
(10 pack years) 
pantoprazole, nintedanib, olmesartan, fluticasone /vilanterol Yes  SCFAs + TNFα 
23.  HLF IPF 59 M T Ex-smoker  
(26 pack years) 
prednisolone, omeprazole, budesonide/formoterol, glycopyrronium 
bromide, perindopril  
Yes  SCFAs + TNFα 
24.  HLF rejection/IPF 61 M T N/A cyclosporin, prednisolone, trimethoprim/ 
sulfamethoxazole, azithromycin, mycophenolate mofetil, posaconazole, 
ezetimibe, pravastatin, irbesartan, metformin, pantoprazole  
No SCFAs + TNFα 
25.  HLF IPF 65 M T Ex-smoker  
(35 pack years) 
omeprazole, sildenafil, budesonide/formoterol, nizatidine, ergocalciferol Yes  SCFAs + TNFα 
26.  HLF pulmonary 
hypertension 
62 F T Non-smoker prednisolone, sildenafil, furosemide, pantoprazole Yes  SCFAs + TNFα 
27.  HLF ILD 40 M T Ex-smoker  
(5 years)  
trimethoprim/sulfamethoxazole, prednisolone, pantoprazole, azathioprine, 
mycophenolic acid,  
No SCFAs + TNFα 
28  HLF COPD 69 F T Ex-smoker  
(100 pack years) 
tiotropium, budesonide/formoterol, atorvastatin, furosemide, baclofen, 
glucosamine, ciclesonide, rabeprazole, terbutaline, perindopril/amlodipine 
No Chronic exposure of SCFAs, 
FFAR3 antagonist  
29. HLF Interstitial 
pneumonitis 
59 M T Non-smoker trimethoprim/sulfamethoxazole, prednisolone, metformin, atorvastatin, 
escitalopram 
Yes Chronic exposure of SCFAs, 
FFAR3 antagonist 
30. HLF IPF 64 M T Ex-smoker  
(70 pack years) 
furosemide, atorvastatin, thyroxine, aspirin, sildenafil, bisoprolol, 
pantoprazole, umeclidinium bromide/vilanterol, olmesartan medoxomil 
Yes  Chronic exposure of SCFAs, 
FFAR3 antagonist 
31. HLF IPF 54 M T Ex-smoker  
(>30 pack years) 
azathioprine, prednisolone, rosuvastatin, trimethoprim, pregabalin, warfarin  No  Chronic exposure of SCFAs, 
FFAR3 antagonist 
32. HLF IPF 63 M T Ex-smoker  
(2 pack years) 
prednisolone, pirfernidone, n-acetylcysteine Yes Chronic exposure of SCFAs, 
FFAR3 antagonist 
33. HLF Adenocarcinoma  57 F R N/A N/A  N/A  Chronic exposure of SCFAs, 
FFAR3 antagonist 
34. HLF Squamous Cell 
Carcinoma 
62 F  R Ex-smoker  
(60 pack years) 
Unknown  No Chronic exposure of SCFAs, 
FFAR3 antagonist 
35. HLF Adenocarcinoma 75 F R Ex-smoker  
(>20 pack years) 
rosuvastatin, aspirin, clopidogrel  No Chronic exposure of SCFAs, 
FFAR3 antagonist 
36. HLF Extrinsic allergic 
alveolites  
69 M T Ex-smoker  
(23 pack years) 
prednisolone, olmesartan, trimethoprim/ 
sulfamethoxazole, aspirin, atorvastatin, temazepam,  venlafaxine  
No SCFAs + TNFα 
37. ASM emphysema  44 F T Ex-smoker  
(15 pack years) 
prednisolone, salbutamol, salmeterol/fluticasone, tiotropium,  N/A  SCFAs + TNFα 
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HLF: human pulmonary fibroblast, ASM: airway smooth muscle, COPD: chronic obstructive pulmonary disease, NSCLC: non-small cell lung carcinoma, IPF: idiopathic pulmonary fibrosis, ILD: Interstitial 
38.  ASM COPD 52 F T Ex-smoker  
(50 pack years) 
venlafaxine, prednisolone, fluticasone/salmeterol, tiotropium No SCFAs + TNFα 
39.  ASM COPD 56 F T Ex-smoker symbicort, tiotropium, terbutaline   SCFAs + TNFα 
40.  ASM Emphysema 59 M T Current  
(35 pack year) 
fluticasone/formoterol, prednisolone, salbutamol, tiotropium, meloxicam, 
doxycycline, ipratropium, glycopyrronium bromide, tapentadol, oxycodone, 
rabeprazole, pregabalin 
No SCFAs + TNFα 
41.  ASM emphysema  62 F T  Ex-smoker  
(40 pack years) 
terbutaline, ciclesonide, tiotropium, formoterol, salbutamol, ipratropium, 
irbesartan, rosuvastatin, prednisolone, azithromycin, pantoprazole 
Yes SCFAs + TNFα 
42.  ASM COPD 65 M T ex-smoker  
(40 pack years) 
salmeterol/fluticasone, tiotropium, pantoprazole,  risedronic acid No SCFAs + TNFα 
43.  ASM IPF 57 M T Ex-smoker  
(40 pack years) 
sildenafil, bumetanide, fluticasone/formoterol, salbutamol Yes SCFAs + TNFα 
44.  ASM IPF 62 M T Ex-smoker  
(10 pack years) 
N/A N/A SCFAs + TNFα 
45.  ASM malignant 
neoplasm 
75 M R Ex-smoker  
(>20 pack years)  
simvastatin, allopurinol, metformin,  Amlodipine, bimatoprost/timolol,  
perindopril, prochlorperazine maleate  
No  SCFAs + TNFα 
46.  ASM healthy donor 65 M T N/A N/A No SCFAs + TNFα 
47.  ASM pulmonary 
hypertension  
30 F T N/A sildenafil, furosemide, epoprostenol, macitentan N/A SCFAs + TNFα 
48.  ASM IPF 58 F T N/A N/A N/A SCFAs + TNFα 
49.  ASM pulmonary 
hypertension 
36 M T Non-smoker dobutamine, bumetanide, empagliflozin, entecavir, folic acid, gabapentin No SCFAs + TNFα 
50.  ASM emphysema  54 M T Ex-smoker  
(60 pack years) 
N/A Yes SCFAs + TNFα 
51.  ASM Asthma 51 M B N/A N/A No SCFAs + TNFα 
52.  ASM IPF 63 F T Ex-smoker  
(15 pack years) 
gabapentin, lorazepam, pantoprazole, prednisolone, sildenafil, 
trimethoprim/ 
sulfamethoxazole 
Yes  SCFAs + TNFα 
53 ASM IPF 62 M T Ex-smoker  
(10 pack years) 
N/A N/A SCFAs + TNFα 
54.  ASM Sarcoidosis 57 M T Non-smoker prednisolone, sildenafil, warfarin, ambrisentan Yes SCFAs + TNFα 
55.  ASM IPF 65 M T Ex-smoker  
(35 pack years) 
omeprazole, sildenafil, budesonide/formoterol, nizatidine Yes  SCFAs + TNFα 
56.  ASM Emphysema 59 M T Current  
(40 pack years) 
salbutamol, tiotropium, mirtazapine, ciclesonide  SCFAs + TNFα 
57.  ASM rejection/IPF 61 M  T N/A cyclosporin, prednisolone, trimethoprim/ 
sulfamethoxazole, azithromycin, mycophenolate mofetil, posaconazole, 
ezetimibe, pravastatin, irbesartan, metformin, pantoprazole  
No SCFAs + TNFα 
58. ASM  ILD 40 M T Ex-smoker  
(5 pack years) 
trimethoprim/sulfamethoxazole, prednisolone, pantoprazole, azathioprine, 
mycophenolic acid, vitamin D, calcium 
No  SCFAs + TNFα 
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Lung Diseases, F: Female, M: Male, T: transplantation, R: resection, B: biopsy, SCFA: short chain fatty acid, FFAR: free fatty acid receptor, WB: western blotting. LTOT: long term oxygen therapy. N/A: data 
not available.   
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Figure legends 
Figure 1. Synergistic increase in cytokine release with combined propionate or butyrate and TNFα 
challenge, than either alone in human pulmonary fibroblasts. Primary human lung  fibroblasts (n = 
10-24 patients) were unstimulated (control) or challenged with short-chain fatty acids (SCFAs) 
propionate (Pr) (0.5mM, 10mM, 25mM) (A, B), butyrate (Bu) (0.01mM, 0.5mM, 10mM) (C, D) or 
acetate (Ac) (0.5mM, 10mM, 25mM) (E, F) in 0.1% BSA-DMEM for 24h with or without TNFα 
(1ng/mL) for another 24h. Cell free supernatants were collected and IL-6 (A, C, E) and CXCL8 (B, D, F) 
release was measured using ELISA. All data are represented as mean ± standard error of the mean. 
All challenges are compared to control and challenges with SCFAs and TNFα are compared to with 
TNFα alone, using a one-way ANOVA and a Bonferroni post-test. Significance is represented as  
**** (p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05).  
Figure 2. Increased IL-6 and CXCL8 mRNA expression upon challenge with propionate and TNFα in 
human pulmonary fibroblasts. Primary human lung  fibroblasts (n = 8 patients) were unstimulated 
(control) or challenged with propionate (Pr) (25mM) in 0.1% BSA-DMEM for 24h with or without 
TNFα (1ng/mL) for another 12h (A, C) or 24h (B, D). Total RNA was extracted and IL-6 (A, B) and 
CXCL8 (C, D) mRNA was measured using qPCR. All data are represented as mean ± standard error of 
the mean. Challenges with Pr and TNFα are compared to challenge with TNFα alone, using a one-
way ANOVA with a Bonferroni post-test. Significance is represented as * (p<0.05). 
Figure 3. SCFAs enhance TNFα-induced IL-6 and CXCL8 release via FFAR3 signalling. Primary human 
lung fibroblasts (n = 14 patients) were unstimulated (control) or challenged with free fatty acid 
receptor (FFAR)2 agonist 4-CMTB (10µM) (A, B) or FFAR3 agonist AR420626 (10µM) (C, D) in 0.1% 
BSA-DMEM for 24h with or without TNFα (1ng/mL) for another 24h. Other cells (n = 8) were pre-
treated with FFAR3 antagonist β-hydroxybutyrate (BOH) (100mM) for 60 minutes, prior to challenge 
with propionate (Pr) 10mM for 24 hours and TNFα (1ng/ml) for another 24h (E, F). Cell free 
supernatants were collected and IL-6 (A, C, E) and CXCL8 (B, D, F) release was measured using ELISA. 
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All data are represented as mean ± standard error of the mean. All challenges are compared to 
control, challenges with FFAR agonist and TNFα are compared to challenge with TNFα alone, and 
challenges with FFAR3 antagonist (BOH) are compared with their respective control in the absence 
of the FFAR3 antagonist using a one-way ANOVA and a Bonferroni post-test. Significance is 
represented as *** (p<0.001), ** (p<0.01) or * (p<0.05). 
Figure 4. Hyperactivation of p38 MAPK upon stimulation with propionate and TNFα. Primary 
human lung fibroblasts (n = 6-10 patients) were unstimulated (control) or challenged with 
propionate (Pr) (25mM), TNFα (1ng/ml) or Pr (25mM) in combination with TNFα (1ng/mL) for 30 
minutes. Whole cell lysates were collected and levels of phosphorylated NF-κB p65 (A), p38 mitogen-
activated protein (MAP) kinase (C), protein kinase B (Akt) (E), extracellular signal-regulated kinases 
(ERK) 1 and 2 (G) or Stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) (I). Total 
NF-κB p65 (B), p38 MAP kinase (D), Akt (F) ERK1 and 2 (H) and SAPK/JNK (J) were also assessed. 
Densitometry was performed and all values were normalized to GAPDH (housekeeping protein), 
detected on the same blots. Data are expressed as fold increase of control, mean ± standard error of 
the mean. Data was analysed using a one-way ANOVA with fisher’s LSD test. Significance is 
represented as *** (p<0.001), ** (p<0.01) or * (p<0.05). Representative western blots are shown 
under each graph.Figure 5. Inhibition of p38 MAPK supresses combined propionate and TNFα-
induced cytokine release in human pulmonary fibroblasts. Primary human lung fibroblasts (n = 10-
11 patients) were treated with or without the cyclooxygenase (COX) inhibitor indomethacin (10µM), 
p38 mitogen-activated protein (MAP) kinase signaling inhibitor SB239063 (3μM), mitogen-activated 
protein (MAP) kinase 1 (MEK1) inhibitor PD98059 (10μM), the c-Jun N-terminal kinase (JNK) inhibitor 
SP600125 (10μM) or the NF-κB inhibitor BAY-117082 (1μM) for 60 minutes before challenge with 
TNFα (1ng/ml) (A, B) or propionate (Pr) (25mM) in combination with TNFα (1ng/ml) (C, D). Cell free 
supernatants were collected after 48h and IL-6 (A, C) and CXCL8 (B, D) release was measured using 
ELISA. All data are represented as mean ± standard error of the mean. All treatments with inhibitor 
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are compared to their respective control in the absence of the inhibitor using a one-way ANOVA and 
a Bonferroni post-test. Significance is represented as ** (p<0.01) or * (p<0.05). 
Figure 6. Chronic exposure to propionate or butyrate enhances TNFα-induced cytokine release in 
human pulmonary fibroblasts. Primary human lung fibroblasts (n = 7 patients) were unstimulated 
(control) or challenged with short-chain fatty acids (SCFAs) propionate (Pr) (25mM (A, B), butyrate 
(Bu) (10mM) (C, D) or acetate (Ac) (25mM) (E, F) in 0.1% BSA-DMEM for 96h with or without TNFα 
(1ng/mL) for another 24h. Cell free supernatants were collected and IL-6 (A, C, E) and CXCL8 (B, D, F) 
release was measured using ELISA. All data are represented as mean ± standard error of the mean. 
All challenges are compared to control and challenges with SCFAs and TNFα are compared to with 
TNFα alone, using a one-way ANOVA and a Bonferroni post-test. Significance is represented as *** 
(p<0.001) ** (p<0.01) or * (p<0.05).  
Figure 7. Greater cytokine release with combined acetate, propionate or butyrate and TNFα 
challenge, than each alone in airway smooth muscle cells. Primary human airway smooth muscle 
cells (n = 8-20 patients) were unstimulated (control) or challenged with short-chain fatty acids 
propionate (Pr) (0.5mM, 10mM, 25mM) (A, B), butyrate (Bu) (0.01mM, 0.5mM, 10mM) (C, D) or 
acetate (Ac) (0.5mM, 10mM, 25mM) (E, F) in 0.1% BSA-DMEM for 24h with or without TNFα 
(1ng/mL) for another 24h. Cell free supernatants were collected and IL-6 (A, C, E) and CXCL8 (B, D, F) 
release was measured using ELISA. All data are represented as mean ± standard error of the mean. 
All challenges are compared to control and challenges with TNFα are compared to their respective 
challenge without TNFα, using a one-way ANOVA and a Bonferroni post-test. Significance is 
represented as **** (p<0.0001), *** (p<0.001), ** (p<0.01) or * (p<0.05). 
 
Figure 8. Propionate suppresses LPS-induced CXCL8 release in THP-1 cells. THP-1 cells (n = 7 
replicates) were unstimulated (control) or challenged with short-chain fatty acids propionate (Pr) 
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(0.5mM, 25mM) (A), butyrate (Bu) (0.01mM, 0.5mM) (B) or acetate (Ac) (0.05mM, 25mM) in 10% 
FBS-RMPI for 24h with LPS (1ng/mL) for another 24h. Cell free supernatants were collected and 
CXCL8 release was measured using ELISA. All data are represented as mean ± standard error of the 
mean. Challenges with LPS are compared to their respective challenge without LPS, using a one-way 
ANOVA and a Bonferroni post-test. Significance is represented as **** (p<0.001). 
 
Short chain fatty acids increase TNFα-induced inflammation 
 
References  
1. Asarat M, Vasiljevic T, Apostolopoulos V, and Donkor O. Short-Chain Fatty Acids Regulate 
Secretion of IL-8 from Human Intestinal Epithelial Cell Lines in vitro. Immunological investigations 44: 
678-693, 2015. 
2. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. The 
Journal of clinical investigation 118: 3546-3556, 2008. 
3. Brightling C, Berry M, and Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for 
asthma. The Journal of allergy and clinical immunology 121: 5-10; quiz 11-12, 2008. 
4. Budden KF, Gellatly SL, Wood DL, Cooper MA, Morrison M, Hugenholtz P, and Hansbro 
PM. Emerging pathogenic links between microbiota and the gut-lung axis. Nature reviews 
Microbiology 15: 55-63, 2017. 
5. Carding S, Verbeke K, Vipond DT, Corfe BM, and Owen LJ. Dysbiosis of the gut microbiota in 
disease. Microbial ecology in health and disease 26: 26191, 2015. 
6. Chang PV, Hao L, Offermanns S, and Medzhitov R. The microbial metabolite butyrate 
regulates intestinal macrophage function via histone deacetylase inhibition. Proceedings of the 
National Academy of Sciences of the United States of America 111: 2247-2252, 2014. 
7. Damera G, Zhao H, Wang M, Smith M, Kirby C, Jester WF, Lawson JA, and Panettieri RA, Jr. 
Ozone modulates IL-6 secretion in human airway epithelial and smooth muscle cells. American 
journal of physiology Lung cellular and molecular physiology 296: L674-683, 2009. 
8. De Cesaris P, Starace D, Riccioli A, Padula F, Filippini A, and Ziparo E. Tumor necrosis factor-
alpha induces interleukin-6 production and integrin ligand expression by distinct transduction 
pathways. The Journal of biological chemistry 273: 7566-7571, 1998. 
9. Engelstoft MS, Park WM, Sakata I, Kristensen LV, Husted AS, Osborne-Lawrence S, Piper 
PK, Walker AK, Pedersen MH, Nohr MK, Pan J, Sinz CJ, Carrington PE, Akiyama TE, Jones RM, Tang 
C, Ahmed K, Offermanns S, Egerod KL, Zigman JM, and Schwartz TW. Seven transmembrane G 
protein-coupled receptor repertoire of gastric ghrelin cells. Molecular metabolism 2: 376-392, 2013. 
10. Ge Q, Moir LM, Black JL, Oliver BG, and Burgess JK. TGFbeta1 induces IL-6 and inhibits IL-8 
release in human bronchial epithelial cells: the role of Smad2/3. Journal of cellular physiology 225: 
846-854, 2010. 
11. Ghorbani P, Santhakumar P, Hu Q, Djiadeu P, Wolever TM, Palaniyar N, and Grasemann H. 
Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth. The European 
respiratory journal 46: 1033-1045, 2015. 
12. Griego SD, Weston CB, Adams JL, Tal-Singer R, and Dillon SB. Role of p38 mitogen-activated 
protein kinase in rhinovirus-induced cytokine production by bronchial epithelial cells. Journal of 
immunology (Baltimore, Md : 1950) 165: 5211-5220, 2000. 
13. Halnes I, Baines KJ, Berthon BS, MacDonald-Wicks LK, Gibson PG, and Wood LG. Soluble 
Fibre Meal Challenge Reduces Airway Inflammation and Expression of GPR43 and GPR41 in Asthma. 
Nutrients 9: 2017. 
14. Ip WK, Wong CK, and Lam CW. Interleukin (IL)-4 and IL-13 up-regulate monocyte 
chemoattractant protein-1 expression in human bronchial epithelial cells: involvement of p38 
mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2 and Janus kinase-2 but 
not c-Jun NH2-terminal kinase 1/2 signalling pathways. Clinical and experimental immunology 145: 
162-172, 2006. 
15. Johnson PR, Armour CL, Carey D, and Black JL. Heparin and PGE2 inhibit DNA synthesis in 
human airway smooth muscle cells in culture. The American journal of physiology 269: L514-519, 
1995. 
16. Johnson PR, and Burgess JK. Airway smooth muscle and fibroblasts in the pathogenesis of 
asthma. Current allergy and asthma reports 4: 102-108, 2004. 
17. Johnson PR, Burgess JK, Ge Q, Poniris M, Boustany S, Twigg SM, and Black JL. Connective 
tissue growth factor induces extracellular matrix in asthmatic airway smooth muscle. American 
journal of respiratory and critical care medicine 173: 32-41, 2006. 
Short chain fatty acids increase TNFα-induced inflammation 
 
18. Kendall RT, and Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and mediators. 
Frontiers in pharmacology 5: 123, 2014. 
19. Kim J, and Remick DG. Tumor necrosis factor inhibitors for the treatment of asthma. Current 
allergy and asthma reports 7: 151-156, 2007. 
20. Kim MH, Kang SG, Park JH, Yanagisawa M, and Kim CH. Short-chain fatty acids activate 
GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. 
Gastroenterology 145: 396-406.e391-310, 2013. 
21. Kimura I, Inoue D, Maeda T, Hara T, Ichimura A, Miyauchi S, Kobayashi M, Hirasawa A, and 
Tsujimoto G. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G 
protein-coupled receptor 41 (GPR41). Proceedings of the National Academy of Sciences of the United 
States of America 108: 8030-8035, 2011. 
22. Klemm C, Bruchhagen C, van Kruchten A, Niemann S, Loffler B, Peters G, Ludwig S, and 
Ehrhardt C. Mitogen-activated protein kinases (MAPKs) regulate IL-6 over-production during 
concomitant influenza virus and Staphylococcus aureus infection. Scientific reports 7: 42473, 2017. 
23. Krimmer D, Ichimaru Y, Burgess J, Black J, and Oliver B. Exposure to biomass smoke extract 
enhances fibronectin release from fibroblasts. PloS one 8: e83938, 2013. 
24. Kuwahara A, Kuwahara Y, Inui T, and Marunaka Y. Regulation of Ion Transport in the 
Intestine by Free Fatty Acid Receptor 2 and 3: Possible Involvement of the Diffuse Chemosensory 
System. International journal of molecular sciences 19: 2018. 
25. Lajunen TK, Jaakkola JJ, and Jaakkola MS. Interleukin 6 SNP rs1800797 associates with the 
risk of adult-onset asthma. Genes and immunity 17: 193-198, 2016. 
26. Li J, Kartha S, Iasvovskaia S, Tan A, Bhat RK, Manaligod JM, Page K, Brasier AR, and 
Hershenson MB. Regulation of human airway epithelial cell IL-8 expression by MAP kinases. 
American journal of physiology Lung cellular and molecular physiology 283: L690-699, 2002. 
27. Li M, van Esch B, Henricks PAJ, Folkerts G, and Garssen J. The Anti-inflammatory Effects of 
Short Chain Fatty Acids on Lipopolysaccharide- or Tumor Necrosis Factor alpha-Stimulated 
Endothelial Cells via Activation of GPR41/43 and Inhibition of HDACs. Frontiers in pharmacology 9: 
533, 2018. 
28. Lin MY, de Zoete MR, van Putten JP, and Strijbis K. Redirection of Epithelial Immune 
Responses by Short-Chain Fatty Acids through Inhibition of Histone Deacetylases. Frontiers in 
immunology 6: 554, 2015. 
29. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, 
Artis D, Xavier RJ, Teixeira MM, and Mackay CR. Regulation of inflammatory responses by gut 
microbiota and chemoattractant receptor GPR43. Nature 461: 1282-1286, 2009. 
30. Masui R, Sasaki M, Funaki Y, Ogasawara N, Mizuno M, Iida A, Izawa S, Kondo Y, Ito Y, 
Tamura Y, Yanamoto K, Noda H, Tanabe A, Okaniwa N, Yamaguchi Y, Iwamoto T, and Kasugai K. G 
protein-coupled receptor 43 moderates gut inflammation through cytokine regulation from 
mononuclear cells. Inflammatory bowel diseases 19: 2848-2856, 2013. 
31. Mirkovic B, Murray MA, Lavelle GM, Molloy K, Azim AA, Gunaratnam C, Healy F, Slattery 
D, McNally P, Hatch J, Wolfgang M, Tunney MM, Muhlebach MS, Devery R, Greene CM, and 
McElvaney NG. The Role of Short-Chain Fatty Acids, Produced by Anaerobic Bacteria, in the Cystic 
Fibrosis Airway. American journal of respiratory and critical care medicine 192: 1314-1324, 2015. 
32. Mirmonsef P, Zariffard MR, Gilbert D, Makinde H, Landay AL, and Spear GT. Short-chain 
fatty acids induce pro-inflammatory cytokine production alone and in combination with toll-like 
receptor ligands. American journal of reproductive immunology (New York, NY : 1989) 67: 391-400, 
2012. 
33. Nastasi C, Candela M, Bonefeld CM, Geisler C, Hansen M, Krejsgaard T, Biagi E, Andersen 
MH, Brigidi P, Odum N, Litman T, and Woetmann A. The effect of short-chain fatty acids on human 
monocyte-derived dendritic cells. Scientific reports 5: 16148, 2015. 
34. Ohira H, Fujioka Y, Katagiri C, Mamoto R, Aoyama-Ishikawa M, Amako K, Izumi Y, Nishiumi 
S, Yoshida M, Usami M, and Ikeda M. Butyrate attenuates inflammation and lipolysis generated by 
Short chain fatty acids increase TNFα-induced inflammation 
 
the interaction of adipocytes and macrophages. Journal of atherosclerosis and thrombosis 20: 425-
442, 2013. 
35. Park J, Goergen CJ, HogenEsch H, and Kim CH. Chronically Elevated Levels of Short-Chain 
Fatty Acids Induce T Cell-Mediated Ureteritis and Hydronephrosis. Journal of immunology 
(Baltimore, Md : 1950) 196: 2388-2400, 2016. 
36. Quay JL, Reed W, Samet J, and Devlin RB. Air pollution particles induce IL-6 gene expression 
in human airway epithelial cells via NF-kappaB activation. American journal of respiratory cell and 
molecular biology 19: 98-106, 1998. 
37. Rutting S, Xenaki D, Lau E, Horvat JC, Wood LG, Hansbro PM, and Oliver BG. Dietary 
omega-6, but not omega-3 polyunsaturated or saturated fatty acids, increase inflammation in 
primary lung mesenchymal cells. American journal of physiology Lung cellular and molecular 
physiology 2018. 
38. Silvestri M, Bontempelli M, Giacomelli M, Malerba M, Rossi GA, Di Stefano A, Rossi A, and 
Ricciardolo FL. High serum levels of tumour necrosis factor-alpha and interleukin-8 in severe asthma: 
markers of systemic inflammation? Clinical and experimental allergy : journal of the British Society 
for Allergy and Clinical Immunology 36: 1373-1381, 2006. 
39. Sina C, Gavrilova O, Forster M, Till A, Derer S, Hildebrand F, Raabe B, Chalaris A, Scheller J, 
Rehmann A, Franke A, Ott S, Hasler R, Nikolaus S, Folsch UR, Rose-John S, Jiang HP, Li J, Schreiber 
S, and Rosenstiel P. G protein-coupled receptor 43 is essential for neutrophil recruitment during 
intestinal inflammation. Journal of immunology (Baltimore, Md : 1950) 183: 7514-7522, 2009. 
40. Smith NJ, Ward RJ, Stoddart LA, Hudson BD, Kostenis E, Ulven T, Morris JC, Trankle C, 
Tikhonova IG, Adams DR, and Milligan G. Extracellular loop 2 of the free fatty acid receptor 2 
mediates allosterism of a phenylacetamide ago-allosteric modulator. Molecular pharmacology 80: 
163-173, 2011. 
41. Syeda F, Liu HY, Tullis E, Liu M, Slutsky AS, and Zhang H. Differential signaling mechanisms 
of HNP-induced IL-8 production in human lung epithelial cells and monocytes. Journal of cellular 
physiology 214: 820-827, 2008. 
42. Thorburn AN, McKenzie CI, Shen S, Stanley D, Macia L, Mason LJ, Roberts LK, Wong CH, 
Shim R, Robert R, Chevalier N, Tan JK, Marino E, Moore RJ, Wong L, McConville MJ, Tull DL, Wood 
LG, Murphy VE, Mattes J, Gibson PG, and Mackay CR. Evidence that asthma is a developmental 
origin disease influenced by maternal diet and bacterial metabolites. Nature communications 6: 
7320, 2015. 
43. Trevor JL, and Deshane JS. Refractory asthma: mechanisms, targets, and therapy. Allergy 69: 
817-827, 2014. 
44. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, Blanchard 
C, Junt T, Nicod LP, Harris NL, and Marsland BJ. Gut microbiota metabolism of dietary fiber 
influences allergic airway disease and hematopoiesis. Nature medicine 20: 159-166, 2014. 
45. Ulven T. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential 
therapeutic targets. Frontiers in endocrinology 3: 111, 2012. 
46. Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, 
Bochnowicz S, Thomas HC, Hay DW, and Griswold DE. SB 239063, a potent p38 MAP kinase 
inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. 
The Journal of pharmacology and experimental therapeutics 293: 281-288, 2000. 
47. Usami M, Kishimoto K, Ohata A, Miyoshi M, Aoyama M, Fueda Y, and Kotani J. Butyrate 
and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha 
secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. 
Nutrition research (New York, NY) 28: 321-328, 2008. 
48. van den Elsen LW, Poyntz HC, Weyrich LS, Young W, and Forbes-Blom EE. Embracing the 
gut microbiota: the new frontier for inflammatory and infectious diseases. Clinical & translational 
immunology 6: e125, 2017. 
Short chain fatty acids increase TNFα-induced inflammation 
 
49. Van Ly D, King NJ, Moir LM, Burgess JK, Black JL, and Oliver BG. Effects of beta(2) Agonists, 
Corticosteroids, and Novel Therapies on Rhinovirus-Induced Cytokine Release and Rhinovirus 
Replication in Primary Airway Fibroblasts. Journal of allergy 2011: 457169, 2011. 
50. Vinolo MA, Ferguson GJ, Kulkarni S, Damoulakis G, Anderson K, Bohlooly YM, Stephens L, 
Hawkins PT, and Curi R. SCFAs induce mouse neutrophil chemotaxis through the GPR43 receptor. 
PloS one 6: e21205, 2011. 
51. Vinolo MA, Rodrigues HG, Hatanaka E, Sato FT, Sampaio SC, and Curi R. Suppressive effect 
of short-chain fatty acids on production of proinflammatory mediators by neutrophils. The Journal of 
nutritional biochemistry 22: 849-855, 2011. 
52. Vinolo MA, Rodrigues HG, Nachbar RT, and Curi R. Regulation of inflammation by short 
chain fatty acids. Nutrients 3: 858-876, 2011. 
53. Wang YH, Xia JL, Wang WM, Yang BW, Cui JF, Wang XD, and Fan J. [TNFalpha induced IL-8 
production through p38 MAPK- NF-kB pathway in human hepatocellular carcinoma cells]. Zhonghua 
gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 19: 912-916, 
2011. 
54. Won YJ, Lu VB, Puhl HL, 3rd, and Ikeda SR. beta-Hydroxybutyrate modulates N-type calcium 
channels in rat sympathetic neurons by acting as an agonist for the G-protein-coupled receptor 
FFA3. The Journal of neuroscience : the official journal of the Society for Neuroscience 33: 19314-
19325, 2013. 
55. Wong JM, de Souza R, Kendall CW, Emam A, and Jenkins DJ. Colonic health: fermentation 
and short chain fatty acids. Journal of clinical gastroenterology 40: 235-243, 2006. 
 
